Cellular immune responses to four doses of percutaneous bacille calmetteguerin in healthy adults

Philip W. Lowry, Teresa S. Ludwig, Jeffrey A. Adams, Michael L. Fitzpatrick, Suzanne M. Grant, Greg A. Andrle, Matthew R. Offerdahl, Sang Nae Cho, David R. Jacobs

Research output: Contribution to journalArticlepeer-review

23 Scopus citations


To explore the hypothesis that low-dose immunization might induce preferential Th1 cell immunity, 76 adults were vaccinated with one of four doses of bacille Calmette-Guerin (BCG): The doses contained very low (1.6 x 105 cfu), low (3.2 x l06 cfu), standard (1.6 x 108 cfu), or high (3.2 X 108 cfu) levels of BCG. Delayed-type hypersensitivity responses occurred 8 weeks after vaccination in 10% of persons given very low or low doses of BCG, compared with 95% and 100% of persons given standard or high doses, respectively. Lymphoproliferative responses, which were increased only for high-dose vaccinees, peaked 2 weeks after vaccination and were directed chiefly against Mycobacterium tuberculosis-secreted proteins, particularly the antigen 85 complex. Significant increases in mycobacteria-specific interferon-γ expression were present 16 weeks after vaccination only for persons given standard or high doses of BCG. Percutaneous BCG appears capable of inducing a temporary Th1-like immune response, but standard or higher dosages are required.

Original languageEnglish (US)
Pages (from-to)138-146
Number of pages9
JournalJournal of Infectious Diseases
Issue number1
StatePublished - 1998


Dive into the research topics of 'Cellular immune responses to four doses of percutaneous bacille calmetteguerin in healthy adults'. Together they form a unique fingerprint.

Cite this